Since 62% of pathogenic/likely pathogenic/conflicting pathogenic SNVs are amenable to correction with a base editor and 87% of these SNVs were found to have a suitable PAM site, gene editing represents a promising therapeutic avenue for CRB1-associated retinal degenerations. The gene discussed is CRB1; the disease is retinal degeneration.